1.99
-0.07(-3.40%)
Currency In USD
| Previous Close | 2.06 |
| Open | 1.97 |
| Day High | 2.06 |
| Day Low | 1.78 |
| 52-Week High | 37.5 |
| 52-Week Low | 1.63 |
| Volume | 244,161 |
| Average Volume | 74,538 |
| Market Cap | 3.53M |
| PE | -0.09 |
| EPS | -22.9 |
| Moving Average 50 Days | 3.82 |
| Moving Average 200 Days | 6.7 |
| Change | -0.07 |
If you invested $1000 in Lyra Therapeutics, Inc. (LYRA) since IPO date, it would be worth $2.14 as of January 14, 2026 at a share price of $1.99. Whereas If you bought $1000 worth of Lyra Therapeutics, Inc. (LYRA) shares 5 years ago, it would be worth $3.63 as of January 14, 2026 at a share price of $1.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lyra Therapeutics Provides Corporate Update
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further development of LYR-210, the Company’s lead product candi
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
GlobeNewswire Inc.
Oct 06, 2025 11:00 AM GMT
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
Jun 27, 2025 12:00 PM GMT
Upfront Gross Proceeds of $5.0 Million, with Up to Approximately $9.8 Million of Additional Gross Proceeds Assuming the Cash Exercise in Full of Private Placement WarrantsWATERTOWN, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (